The presence of multiple new COVID-19 variants and subvariants has rapidly shifted strategies for treatment and prevention. Clinicians struggle to remain up to date with a rapidly changing field that has remained a public health concern, including guidelines, Emergency Use Authorization status, and challenges with logistical implementation. In this webcast series, regional faculty present data on and discuss current evidence and regulatory status for anti-SARS-CoV-2 monoclonal antibodies for treatment and prevention and available antivirals for treatment, updates to National Institutes of Health guidelines on patient identification, and strategies to reduce health care disparities.
The educational design of this activity addresses the needs of infectious disease specialists, internal medicine physicians, transplant specialists, oncologist, pharmacists, and other clinicians involved in managing patients who are at heightened risk for poor COVID-19 outcomes.
Upon completion of this activity, the participant should be better able to:
Discuss recent trial data and current regulatory status for anti-SARS-CoV-2 monoclonal antibodies
Identify candidates for pre-exposure prophylaxis or treatment with anti-SARS-CoV-2 monoclonal antibodies, including immunocompromised patients
Create proactive plans with patients, other clinicians, and healthcare systems to ensure prompt and equitable use of anti-SARS-CoV-2 monoclonal antibodies for pre-exposure prophylaxis or treatment